Continuous antiretroviral therapy decreases bone mineral density
- 31 July 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 23 (12), 1519-1529
- https://doi.org/10.1097/qad.0b013e32832c1792
Abstract
Objectives: To assess the effects of antiretroviral therapy (ART) on bone mineral density (BMD) Design: Randomized comparison of continuous ART (viral suppression group; VS) with intermittent ART (drug conservation group; DC) Setting: Outpatient clinics in the United States, Australia, and Spain. Participants: Participants in the Strategies for Management of Antiretroviral Therapy (SMART) Body Composition substudy. Main outcome measures: Annual hip and spine BMD by dual-energy radiographic absorptiometry (DXA) and spine BMD by quantitative computed tomography (qCT). Methods: Comparisons were by intention-to-treat analysis, using longitudinal models for change in BMD. Risk factors for BMD loss were evaluated. Results: The 214 participants (median 44 years, 19% female participants, 73% on ART; median T-scores −0.5 total hip, −0.7 spine DXA, −0.9 spine qCT; 98 randomized to VS and 116 to DC) were followed for a mean 2.4 years. With continuous ART, BMD declined per year by 0.8% (hip), 0.4% (spine DXA), and 2.4% (spine qCT). BMD declined significantly less with intermittent ART. Estimated DC minus VS group differences in mean BMD change through follow-up were 1.4% [hip; 95% confidence interval (CI) 0.6–2.3; P = 0.002], 1.3% (spine DXA; 95% CI 0.1–2.4, P = 0.03), and 3.0% (spine qCT; 95% CI 0.8–5.2, P = 0.007). No consistent drug-specific association with BMD decline was found. In the parent study, 10 of 2753 participants in the VS group and two of 2720 in the DC group reported serious fractures (hazard ratio 4.9; 95% CI 1.1–22.5; P = 0.04). Conclusion: Continuous ART is associated with decline in BMD and possibly more fractures relative to intermittent, CD4 cell count-guided ART.Keywords
This publication has 38 references indexed in Scilit:
- Fracture Prevalence among Human Immunodeficiency Virus (HIV)-InfectedVersusNon-HIV-Infected Patients in a Large U.S. Healthcare SystemJournal of Clinical Endocrinology & Metabolism, 2008
- Effect of Reducing the Dose of Stavudine on Body Composition, Bone Density, and Markers of Mitochondrial Toxicity in HIV‐Infected Subjects: A Randomized, Controlled StudyClinical Infectious Diseases, 2008
- Reduced bone mineral density in HIV-infected patients: prevalence and associated factorsAIDS, 2008
- Risk of side effects associated with the use of nevirapine in treatment‐naïve patients, with respect to gender and CD4 cell countHIV Medicine, 2008
- The role of DXA bone density scans in the diagnosis and treatment of osteoporosisPublished by Oxford University Press (OUP) ,2007
- Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infectionAIDS, 2007
- Longitudinal Analysis of Bone Density in Human Immunodeficiency Virus-Infected WomenJournal of Clinical Endocrinology & Metabolism, 2006
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- AZT Enhances Osteoclastogenesis and Bone LossAIDS Research and Human Retroviruses, 2004
- BMD Is Reduced in HIV-Infected Men Irrespective of TreatmentJournal of Bone and Mineral Research, 2004